MedTrace Logo

Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty

NCT03316482 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2020-06-02

No results posted yet for this study

Summary

A multicenter, open-label, prospective study to evaluate the safety and efficacy of leuprorelin acetate DPS (Leuplin DPS) treatment quarterly in patients with central precocious puberty

Conditions

  • Central Precocious Puberty

Interventions

DRUG

Leuplin DPS 11.25mg

Leuplin DPS 11.25mg s.c. every 12 weeks

Sponsors & Collaborators

  • Jin Soon Hwang

    lead OTHER

Principal Investigators

  • Jin Soon Hwang, MD, PhD · Ajoun university hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-11
Primary Completion
2019-08-29
Completion
2019-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03316482 on ClinicalTrials.gov